Johnson & Johnson Ups The Dosage

The pharmaceutical business continues to drive nearly all of the growth at this healthcare giant.

Jul 15, 2014 at 4:00PM

Healthcare giant Johnson & Johnson (NYSE:JNJ) continues to prosper by virtue of its strong pharmaceutical business as the consumer and device business continue to languish. Not only does Johnson & Johnson offer a strong internal pipeline that can help maintain that momentum, the company has more than enough liquidity to acquire/license drugs if it should want to go that route. A real turnaround in devices appears to be a ways off, though, and these shares don't scream "bargain" in the meantime.

Good results, in brief
Johnson & Johnson reported better than expected results, with revenue up more than 9% as reported and closer to 10% on an organic basis. Gross margin was a tad soft (about 0.3% below expectations), but operating income rose 18% and exceeded expectations by about 10%, with a 200bp beat on operating margin driven by scant 2% growth in SG&A spending. 

Drugs lead the way...
Once again Johnson & Johnson saw its performance driven by the pharmaceutical business. Sales rose 21% and generated about 80% of the company's outperformance versus the average sell-side estimate. Remicade remains a key drug (about 20% of total drug sales) and continues to grow (up 8%), while newer drugs Olysio (up 135% qoq), Zytiga (up 42%), and Xarelto (up 91%) continue to generate strong growth.

Olysio has been enjoying a strong tailwind from demand for Gilead's Sovaldi and continues to beat expectations. Zytiga enjoys around one-third market share in castration-resistant prostate cancer , while Xarelto has staked out an impressive 60% share among novel anticoagulants.

... but devices still lag
Johnson & Johnson has had a hard time getting growth going again in the device space. This is in part a "market problem", but the company nevertheless came in a little weaker than expected. Sales were up 1% this quarter, led by Cardio (up 7%) as the company continues to enjoy the perks of market leadership in the growing catheter ablation market (electrophysiology sales were up 14%).

Orthopedic sales were up about 3% on an organic basis, with slightly better recon growth driven by solid hip and knee growth outside the U.S. (up 6% and 4%). U.S. results were less inspiring (up 4% and flat), and spine was a little disappointing. Johnson & Johnson outdid Biomet in hips (Biomet is being acquired by Zimmer, but the deal has not been cleared yet), but I'll be very interested to see how Stryker compares in knees, as Stryker has been doing quite well in hips but rather poorly in knees.

Vision was weak (down 3%) due in part to customers taking on inventory in the first quarter ahead of changes in taxes and prices. Diabetes remains weak (down 5%) as reimbursement continues to punish devices (testing strips and insulin pumps).

Surgical was surprisingly and disappointingly weak (down 1%), as management really didn't telegraph much weakness during their device analyst day in late May. Some of this weakness is due to declines in women's health (which has affected Covidien, Boston Scientific, and Bard as well to varying degrees). We won't know for sure until we see Covidien's results, but there may be some incremental share loss going on here as well, to the benefit of Covidien.

Olysio may not last, but Johnson & Johnson is committed to the pharmaceutical space
Olysio continues to surprise analysts, as this protease inhibitor is riding the coattails of Gilead's Sovaldi. While payers are reimbursing the $150,000 cost of the combo (albeit not without complaint), it will likely be difficult for Johnson & Johnson to maintain this momentum once Gilead launches its once-daily combo regimen later this year (not to mention the eventual launch of AbbVie's combo).

Outside of Olysio, the company still has a lot going on in the pipeline, including a 3-month formulation of Invega Sustenna, data on daratumumab (myeloma), sirkumab (rheumatoid arthritis), ARN-059 (prostate cancer), esketamine (depression), and guselkumab (psoriasis). Johnson & Johnson is also in a position to license or acquire as biotech valuations continue to decline, with oncology a probable target.

The bottom line
Johnson & Johnson is not strikingly cheap. A look at EV/revenue (a popular valuation methodology in med-tech) shows the stock trading at 3.75x expected 12-month revenue – a pretty healthy valuation. Though this company has a good pharmaceutical business (and a solid pipeline) and generates ample free cash flow, it's hard to work up a lot of enthusiasm about the valuation absent more momentum in the Consumer or Device businesses.

A much more exciting opportunity
Johnson & Johnson had a good quarter, but everyone knows about the stock. And that's a problem, because the best investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool’s new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.

Stephen D. Simpson, CFA has no position in any stocks mentioned. The Motley Fool recommends Covidien, Gilead Sciences, and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

A Financial Plan on an Index Card

Keeping it simple.

Aug 7, 2015 at 11:26AM

Two years ago, University of Chicago professor Harold Pollack wrote his entire financial plan on an index card.

It blew up. People loved the idea. Financial advice is often intentionally complicated. Obscurity lets advisors charge higher fees. But the most important parts are painfully simple. Here's how Pollack put it:

The card came out of chat I had regarding what I view as the financial industry's basic dilemma: The best investment advice fits on an index card. A commenter asked for the actual index card. Although I was originally speaking in metaphor, I grabbed a pen and one of my daughter's note cards, scribbled this out in maybe three minutes, snapped a picture with my iPhone, and the rest was history.

More advisors and investors caught onto the idea and started writing their own financial plans on a single index card.

I love the exercise, because it makes you think about what's important and forces you to be succinct.

So, here's my index-card financial plan:


Everything else is details. 

Something big just happened

I don't know about you, but I always pay attention when one of the best growth investors in the world gives me a stock tip. Motley Fool co-founder David Gardner (whose growth-stock newsletter was rated #1 in the world by The Wall Street Journal)* and his brother, Motley Fool CEO Tom Gardner, just revealed two brand new stock recommendations moments ago. Together, they've tripled the stock market's return over 12+ years. And while timing isn't everything, the history of Tom and David's stock picks shows that it pays to get in early on their ideas.

Click here to be among the first people to hear about David and Tom's newest stock recommendations.

*"Look Who's on Top Now" appeared in The Wall Street Journal which references Hulbert's rankings of the best performing stock picking newsletters over a 5-year period from 2008-2013.

Compare Brokers